Savara(US:SVRA) Globenewswire·2025-10-15 22:00Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud following the FDA's refusal to file letter regarding its MOLBREEVI BLA, which led to a significant drop in share price [3][4]. Group 1: Company Announcement - On May 27, 2025, Savara announced that it received a refusal to file letter from the FDA for the MOLBREEVI BLA, indicating that the submission was not sufficiently complete for review [3]. - Following this announcement, Savara's share price fell by $0.90, or approximately 31.69%, from $2.84 on May 23, 2025, to $1.94 on May 27, 2025 [3]. Group 2: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities between March 7, 2024, and May 23, 2025, alleging that Savara made false or misleading statements regarding the MOLBREEVI BLA [4]. - Specific allegations include that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [4]. - The lawsuit also claims that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4].